Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board

Autor(es):Mostrar menos -

Xavier, Camila B. ; Link, Rudinei ; Abreu, Leonilia ; Bettoni, Fabiana ; Marson, Fabiane ; Galante, Pedro A. F. ; Masotti, Cibele ; Amano, Mariane T. ; de Molla, Vinicius ; Camargo, Anamaria A. ; Asprino, Paula F. ; Sabbaga, Jorge

• Tipo de documento: Artigo Científico
• Fonte: ONCOLOGIST; v. N/A, p. 4-pg., 2023-05-09.

Resumo

Objective Li-Fraumeni syndrome (LFS) is a pan-cancer predisposition syndrome caused by germline pathogenic variants in the gene TP53. The interpretation of TP53 variants in clinical scenarios outside the classic LFS criteria may be challenging. Here, we report a patient affected by 2 primary cancers at later ages, who harbored a likely pathogenic TP53 at low allele frequency detected in a blood sample. Methods The Molecular Tumor Board committee at our institution revisited the case of a patient who was enrolled in a research protocol for the investigation of genetic conditions associated with neuroendocrine tumors. Clinical, familial, and molecular data were reviewed. The patient received germline testing using a next generation sequencing multi-gene panel and was incidentally found to harbor a TP53 likely pathogenic variant, with 22% of variant allele fraction. Additional samples, including a second blood sample, oral swab, and saliva, were collected for DNA analysis. A new TP53 sequencing round was performed with the attempt to distinguish between a true constitutional germline variant and a somatically acquired variant due to aberrant clonal expansion of bone marrow precursors. Results Patient's personal and familial history of cancer did not meet classic nor Chompret LFS criteria. Environmental risk factors for cancer were identified, such as alcohol abuse and tobacco exposure. The TP53 variant initially found in the next-generation sequencing was confirmed by Sanger sequencing in the previous DNA sample extracted from blood for the first analysis and in a second blood sample collected 6 years later. The TP53 variant was not detected in the DNA extracted from the oral swab and saliva samples. Conclusion Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution. This case report describes a patient with a history of 2 primary cancers who harbored a likely pathogenic TP53 variant with low variant allele frequency in a blood sample. Such a result could have been misinterpreted as a Li-Fraumeni case, but other tests were conducted to elucidate the case. (AU)

• Processo FAPESP: 19/04927-8 - Caracterização da variante D184Y no gene BRIP1 em família com histórico de câncer de mama e pâncreas.
• Beneficiário: Paula Fontes Asprino
• Modalidade de apoio: Auxílio à Pesquisa - Regular